PubMed

Bladder cancer: narrowing the gap between evidence and practice.

Hussain MH, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, O'Donnell MA, Siefker-Radtke AO, Theodorescu D, Dinney CP.

J Clin Oncol. 2009 Dec 1;27(34):5680-4. Epub 2009 Oct 26. No abstract available. PMID: 19858384 [PubMed - in process]Related articles

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R.

Clin Cancer Res. 2009 Oct 1;15(19):6277-83. Epub 2009 Sep 22.PMID: 19773375 [PubMed - in process]Related articles

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.

Schelman WR, Liu G, Wilding G, Morris T, Phung D, Dreicer R.

Invest New Drugs. 2009 Sep 19. [Epub ahead of print]PMID: 19763400 [PubMed - as supplied by publisher]Related articles

Second-line chemotherapy for advanced urothelial cancer: because we should or because we can?

Dreicer R.

J Clin Oncol. 2009 Sep 20;27(27):4444-5. Epub 2009 Aug 17. No abstract available. PMID: 19687324 [PubMed - indexed for MEDLINE]Related articles

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.

Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, Wilding G.

Cancer. 2009 Sep 15;115(18):4090-5.PMID: 19536901 [PubMed - indexed for MEDLINE]Related articles

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.

Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R, Finke JH.

Clin Cancer Res. 2009 Mar 15;15(6):2148-57. Epub 2009 Mar 10.PMID: 19276286 [PubMed - indexed for MEDLINE]Related articles

Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.

Shepard DR, Dreicer R, Garcia J, Elson P, Magi-Galluzzi C, Raghavan D, Stephenson AJ, Klein EA.

J Urol. 2009 Apr;181(4):1672-7; discussion 1677. Epub 2009 Feb 23.PMID: 19230915 [PubMed - indexed for MEDLINE]Related articles

Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.

Weight CJ, Garcia JA, Hansel DE, Fergany AF, Campbell SC, Gong MC, Jones JS, Klein EA, Dreicer R, Stephenson AJ.

Cancer. 2009 Feb 15;115(4):792-9.PMID: 19127557 [PubMed - indexed for MEDLINE]Related articles

Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.

Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC.

J Urol. 2009 Feb;181(2):518-23; discussion 523. Epub 2008 Dec 18.PMID: 19100579 [PubMed - indexed for MEDLINE]Related articles

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.

Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, Limacher JM, Squiban P, Pantuck A.

Invest New Drugs. 2009 Aug;27(4):379-86. Epub 2008 Oct 18.PMID: 18931824 [PubMed - indexed for MEDLINE]Related articles

Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.

Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, Wood L, Elson P, Garcia J, Dreicer R, Bukowski R.

Clin Cancer Res. 2008 Oct 15;14(20):6674-82.PMID: 18927310 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.

George S, Dreicer R, Au JJ, Shen T, Rini BI, Roman S, Cooney MM, Mekhail T, Elson P, Wientjes GM, Ganapathi R, Bukowski RM.

Clin Genitourin Cancer. 2008 Sep;6(2):79-85.PMID: 18824429 [PubMed - indexed for MEDLINE]Related articles

Systems pathology and predicting outcome after radical prostatectomy.

Klein EA, Stephenson AJ, Raghavan D, Dreicer R.

J Clin Oncol. 2008 Aug 20;26(24):3916-7. No abstract available. PMID: 18711177 [PubMed - indexed for MEDLINE]Related articles

HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases.

Hansel DE, Swain E, Dreicer R, Tubbs RR.

Am J Clin Pathol. 2008 Aug;130(2):274-81.PMID: 18628098 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.

Tamaskar I, Mekhail T, Dreicer R, Olencki T, Roman S, Elson P, Bukowski RM.

Invest New Drugs. 2008 Dec;26(6):553-9. Epub 2008 Jul 15.PMID: 18626572 [PubMed - indexed for MEDLINE]Related articles

Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.

Rini BI, Choueiri TK, Elson P, Khasawneh MK, Cotta C, Unnithan J, Wood L, Mekhail T, Garcia J, Dreicer R, Bukowski RM.

Cancer. 2008 Sep 15;113(6):1309-14.PMID: 18618496 [PubMed - indexed for MEDLINE]Related articlesFree article

Advanced bladder cancer: so many drugs, so little progress : what's wrong with this picture?

Dreicer R.

Cancer. 2008 Sep 15;113(6):1275-7. No abstract available. PMID: 18615663 [PubMed - indexed for MEDLINE]Related articlesFree article

Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer.

Dreicer R.

Urol Oncol. 2008 Jul-Aug;26(4):426-9. Review.PMID: 18593622 [PubMed - indexed for MEDLINE]Related articles

Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.

Garcia JA, Klein EA, Magi-Galluzzi C, Elson P, Triozzi P, Dreicer R.

Clin Cancer Res. 2008 May 15;14(10):3052-9.PMID: 18483371 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.

Dreicer R, Li H, Cooney MM, Wilding G, Roth BJ; Eastern Cooperative Oncology Group.

Cancer. 2008 Jun 15;112(12):2671-5.PMID: 18459175 [PubMed - indexed for MEDLINE]Related articlesFree article

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group.

J Clin Oncol. 2008 Mar 1;26(7):1148-59.PMID: 18309951 [PubMed - indexed for MEDLINE]Related articles

Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.

Bradley DA, Dunn R, Nanus D, Stadler W, Dreicer R, Rosenberg J, Smith DC, Hussain M.

Clin Genitourin Cancer. 2007 Dec;5(7):460-3.PMID: 18272031 [PubMed - indexed for MEDLINE]Related articles

A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.

Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B.

J Urol. 2008 Mar;179(3):906-10; discussion 910. Epub 2008 Jan 22.PMID: 18207194 [PubMed - indexed for MEDLINE]Related articles

Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases.

Lagwinski N, Thomas A, Stephenson AJ, Campbell S, Hoschar AP, El-Gabry E, Dreicer R, Hansel DE.

Am J Surg Pathol. 2007 Dec;31(12):1777-87.PMID: 18043032 [PubMed - indexed for MEDLINE]Related articles

Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder.

Dhar NB, Jones JS, Reuther AM, Dreicer R, Campbell SC, Sanii K, Klein EA.

BJU Int. 2008 Apr;101(8):969-72. Epub 2007 Nov 13.PMID: 18005201 [PubMed - indexed for MEDLINE]Related articles

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM.

J Urol. 2008 Jan;179(1):81-6; discussion 86. Epub 2007 Nov 12.PMID: 17997441 [PubMed - indexed for MEDLINE]Related articles

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.

Tamaskar I, Bukowski R, Elson P, Ioachimescu AG, Wood L, Dreicer R, Mekhail T, Garcia J, Rini BI.

Ann Oncol. 2008 Feb;19(2):265-8. Epub 2007 Oct 24.PMID: 17962201 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.

George S, Hutson TE, Mekhail T, Wood L, Finke J, Elson P, Dreicer R, Bukowski RM.

Cancer Chemother Pharmacol. 2008 Jul;62(2):347-54. Epub 2007 Oct 2.PMID: 17909807 [PubMed - indexed for MEDLINE]Related articles

Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.

Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA.

Cancer. 2007 Sep 15;110(6):1248-54.PMID: 17674353 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.

Beer TM, Higano CS, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L, Hannah AL.

Invest New Drugs. 2007 Dec;25(6):565-70. Epub 2007 Jul 7.PMID: 17618407 [PubMed - indexed for MEDLINE]Related articles

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group.

Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G; Eastern Cooperative Oncology Group.

Cancer. 2007 Aug 15;110(4):759-63.PMID: 17594721 [PubMed - indexed for MEDLINE]Related articlesFree article

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.

Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA.

J Urol. 2007 May;177(5):1777-81.PMID: 17437819 [PubMed - indexed for MEDLINE]Related articles

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.

Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J.

Support Care Cancer. 2007 Nov;15(11):1293-300. Epub 2007 Apr 14.PMID: 17436025 [PubMed - indexed for MEDLINE]Related articles

The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis.

Gilligan T, Dreicer R.

Semin Oncol. 2007 Apr;34(2):145-53. Review.PMID: 17382798 [PubMed - indexed for MEDLINE]Related articles

Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.

Dreicer R, Petrylak D, Agus D, Webb I, Roth B.

Clin Cancer Res. 2007 Feb 15;13(4):1208-15.PMID: 17317831 [PubMed - indexed for MEDLINE]Related articlesFree article

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators.

J Clin Oncol. 2007 Feb 20;25(6):669-74.PMID: 17308271 [PubMed - indexed for MEDLINE]Related articles

Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors.

Dreicer R.

Curr Oncol Rep. 2007 Mar;9(2):120-3. Review.PMID: 17288877 [PubMed - indexed for MEDLINE]Related articles

Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.

Dreicer R.

Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S19-23. Review.PMID: 17239280 [PubMed - indexed for MEDLINE]Related articles

Chemotherapy for muscle-invasive bladder cancer in the perioperative setting: current standards.

Dreicer R.

Urol Oncol. 2007 Jan-Feb;25(1):72-5.PMID: 17208143 [PubMed - indexed for MEDLINE]Related articles

Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.

Segota E, Mekhail T, Olencki T, Hutson TE, Dreicer R, Wacker B, Osterwalder B, Elson P, Zhou M, Bukowski RM.

Urol Oncol. 2007 Jan-Feb;25(1):46-52.PMID: 17208138 [PubMed - indexed for MEDLINE]Related articles

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM.

J Natl Cancer Inst. 2007 Jan 3;99(1):81-3.PMID: 17202116 [PubMed - indexed for MEDLINE]Related articlesFree article

Systemic chemotherapy for advanced bladder cancer: update and controversies.

Garcia JA, Dreicer R.

J Clin Oncol. 2006 Dec 10;24(35):5545-51. Review.PMID: 17158540 [PubMed - indexed for MEDLINE]Related articles

Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors.

Kalmadi S, Davis M, Dowlati A, O'Keefe S, Cline-Burkhardt M, Pelley RJ, Borden E, Dreicer R, Bukowski R, Mekhail T.

Invest New Drugs. 2007 Jun;25(3):211-6. Epub 2006 Nov 11.PMID: 17103043 [PubMed - indexed for MEDLINE]Related articles

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.

Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM.

Cancer. 2006 Dec 1;107(11):2609-16.PMID: 17075879 [PubMed - indexed for MEDLINE]Related articlesFree article

E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels.

Dreicer R, Carducci M.

Rev Urol. 2003;5 Suppl 2:S35-41.PMID: 16986045 [PubMed - in process]Related articlesFree article

Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer.

Klein EA, Dreicer R.

Rev Urol. 2003;5 Suppl 2:S22-7.PMID: 16986042 [PubMed - in process]Related articlesFree article

E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels.

Dreicer R, Carducci M.

Rev Urol. 2003;5 Suppl 3:S52-8.PMID: 16985951 [PubMed - in process]Related articlesFree article

Initial experience with single-agent docetaxel as neoadjuvant therapy in men with locally advanced prostate cancer.

Klein EA, Dreicer R.

Rev Urol. 2003;5 Suppl 3:S22-7.PMID: 16985946 [PubMed - in process]Related articlesFree article

Chemotherapy for advanced prostate cancer: docetaxel and beyond.

Dreicer R.

Hematol Oncol Clin North Am. 2006 Aug;20(4):935-46, x. Review.PMID: 16861124 [PubMed - indexed for MEDLINE]Related articles

Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.

Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D, Crawford ED.

Cancer. 2006 Jun 15;106(12):2624-9.PMID: 16688776 [PubMed - indexed for MEDLINE]Related articlesFree article